BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
- PMID: 20400477
- DOI: 10.1093/carcin/bgq069
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
Abstract
BRCA1 and BRCA2 are tumor suppressor genes, familial mutations in which account for approximately 5% of breast cancer cases in the USA annually. Germ line mutations in BRCA1 that truncate or inactivate the protein lead to a cumulative risk of breast cancer, by age 70, of up to 80%, whereas the risk of ovarian cancer is 30-40%. For germ line BRCA2 mutations, the breast cancer cumulative risk approaches 50%, whereas for ovarian cancers, it is between 10 and 15%. Both BRCA1 and BRCA2 are involved in maintaining genome integrity at least in part by engaging in DNA repair, cell cycle checkpoint control and even the regulation of key mitotic or cell division steps. Unsurprisingly, the complete loss of function of either protein leads to a dramatic increase in genomic instability. How they function in maintaining genome integrity after the onset of DNA damage will be the focus of this review.
Similar articles
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Hereditary ovarian cancer.Hum Pathol. 2005 Aug;36(8):861-70. doi: 10.1016/j.humpath.2005.06.006. Hum Pathol. 2005. PMID: 16112002 Review.
-
Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2339-42. doi: 10.1158/1055-9965.EPI-09-0447. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19661094
-
Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.Curr Womens Health Rep. 2003 Feb;3(1):27-32. Curr Womens Health Rep. 2003. PMID: 12521547 Review.
-
Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.Hum Mutat. 2003 Aug;22(2):121-8. doi: 10.1002/humu.10238. Hum Mutat. 2003. PMID: 12872252
Cited by
-
The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer.Genome Res. 2015 Apr;25(4):488-503. doi: 10.1101/gr.185926.114. Epub 2015 Feb 4. Genome Res. 2015. PMID: 25653311 Free PMC article.
-
Conditional in vivo deletion of LYN kinase has little effect on a BRCA1 loss-of-function-associated mammary tumour model.Dis Model Mech. 2024 Jan 1;17(1):dmm050211. doi: 10.1242/dmm.050211. Epub 2024 Jan 25. Dis Model Mech. 2024. PMID: 38149669 Free PMC article.
-
Integrated sequence and expression analysis of ovarian cancer structural variants underscores the importance of gene fusion regulation.BMC Med Genomics. 2015 Jul 17;8:40. doi: 10.1186/s12920-015-0118-9. BMC Med Genomics. 2015. PMID: 26177635 Free PMC article.
-
First-degree family history of breast cancer is associated with prostate cancer risk: a systematic review and meta-analysis.BMC Cancer. 2019 Sep 2;19(1):871. doi: 10.1186/s12885-019-6055-9. BMC Cancer. 2019. PMID: 31477094 Free PMC article.
-
Targeting the lysosome by an aminomethylated Riccardin D triggers DNA damage through cathepsin B-mediated degradation of BRCA1.J Cell Mol Med. 2019 Mar;23(3):1798-1812. doi: 10.1111/jcmm.14077. Epub 2018 Dec 18. J Cell Mol Med. 2019. PMID: 30565390 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous